Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mesocarb - Melior Pharmaceuticals

Drug Profile

Mesocarb - Melior Pharmaceuticals

Alternative Names: Armesocarb; MLR-1019

Latest Information Update: 02 Aug 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Melior Discovery
  • Developer Melior Pharmaceuticals, Inc.
  • Class Antiparkinsonians; Imines; Oxadiazoles; Sleep disorder therapies; Small molecules
  • Mechanism of Action Dopamine uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Parkinson's disease
  • Preclinical Sleep disorders
  • Market Withdrawal Psychiatric disorders

Most Recent Events

  • 02 Aug 2021 Melior Pharmaceuticals and Adhera Therapeutics complete a licensing agreement for mesocarb for Parkinson's disease
  • 08 Jun 2021 Melior Pharmaceuticals Inc. and Adhera Therapeutics agree to co-develop mesocarb for Parkinson's disease in June 2021
  • 28 Jan 2020 Preclinical development in Parkinson's disease is ongoing in USA (Melior Pharmaceuticals Pipeline, January 2020)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top